-$0.45 EPS Expected for Translate Bio Inc (NASDAQ:TBIO) This Quarter

Brokerages expect Translate Bio Inc (NASDAQ:TBIO) to report ($0.45) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Translate Bio’s earnings, with the highest EPS estimate coming in at ($0.34) and the lowest estimate coming in at ($0.54). Translate Bio posted earnings per share of ($0.97) in the same quarter last year, which indicates a positive year-over-year growth rate of 53.6%. The company is expected to issue its next earnings report on Thursday, November 14th.

On average, analysts expect that Translate Bio will report full year earnings of ($2.13) per share for the current fiscal year, with EPS estimates ranging from ($2.42) to ($1.86). For the next fiscal year, analysts forecast that the business will post earnings of ($1.79) per share, with EPS estimates ranging from ($1.96) to ($1.54). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Translate Bio.

Translate Bio (NASDAQ:TBIO) last announced its earnings results on Wednesday, July 31st. The company reported ($0.57) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.09). Translate Bio had a negative net margin of 2,696.98% and a negative return on equity of 84.05%. The business had revenue of $1.17 million during the quarter, compared to analyst estimates of $1.73 million.

A number of analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $21.00 target price on shares of Translate Bio in a research note on Thursday. Jefferies Financial Group began coverage on Translate Bio in a research note on Monday, July 22nd. They issued a “buy” rating and a $20.00 target price for the company. Zacks Investment Research upgraded Translate Bio from a “sell” rating to a “hold” rating in a report on Tuesday, July 16th. Finally, Roth Capital began coverage on Translate Bio in a report on Tuesday, June 18th. They issued a “buy” rating and a $25.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Translate Bio presently has a consensus rating of “Buy” and a consensus target price of $22.75.

A number of institutional investors have recently bought and sold shares of TBIO. Rhumbline Advisers purchased a new stake in shares of Translate Bio during the fourth quarter worth about $77,000. BlackRock Inc. grew its holdings in shares of Translate Bio by 130.2% during the fourth quarter. BlackRock Inc. now owns 982,405 shares of the company’s stock worth $7,367,000 after buying an additional 555,635 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Translate Bio by 101.4% in the fourth quarter. Bank of New York Mellon Corp now owns 27,968 shares of the company’s stock worth $210,000 after acquiring an additional 14,081 shares during the last quarter. Northern Trust Corp boosted its position in shares of Translate Bio by 12.4% in the fourth quarter. Northern Trust Corp now owns 111,339 shares of the company’s stock worth $835,000 after acquiring an additional 12,242 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Translate Bio by 139.0% in the fourth quarter. Geode Capital Management LLC now owns 117,432 shares of the company’s stock worth $880,000 after acquiring an additional 68,300 shares during the last quarter. Institutional investors and hedge funds own 57.90% of the company’s stock.

Shares of NASDAQ:TBIO traded up $0.28 during midday trading on Friday, reaching $8.31. The company’s stock had a trading volume of 430,466 shares, compared to its average volume of 165,651. Translate Bio has a fifty-two week low of $4.81 and a fifty-two week high of $14.34. The company has a debt-to-equity ratio of 1.34, a quick ratio of 7.69 and a current ratio of 7.69. The stock’s fifty day simple moving average is $10.50.

Translate Bio Company Profile

Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.

Further Reading: Cryptocurrencies

Get a free copy of the Zacks research report on Translate Bio (TBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Translate Bio (NASDAQ:TBIO)

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.